BioCentury
ARTICLE | Company News

Cell Pathways, Aventis sales and marketing update

July 10, 2000 7:00 AM UTC

CLPA obtained rights to market AVE's Nilandron nilutamide testosterone blocker to treat prostate cancer to urologists in the U.S. ...